These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 32558174)

  • 1. Effects of mTOR inhibitor-related proteinuria on progression of cardiac allograft vasculopathy and outcomes among heart transplant recipients.
    Asleh R; Alnsasra H; Lerman A; Briasoulis A; Pereira NL; Edwards BS; Toya T; Stulak JM; Clavell AL; Daly RC; Kushwaha SS
    Am J Transplant; 2021 Feb; 21(2):626-635. PubMed ID: 32558174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypercholesterolemia after conversion to sirolimus as primary immunosuppression and cardiac allograft vasculopathy in heart transplant recipients.
    Asleh R; Briasoulis A; Pereira NL; Edwards BS; Frantz RP; Daly RC; Lerman A; Kushwaha SS
    J Heart Lung Transplant; 2018 Nov; 37(11):1372-1380. PubMed ID: 30174165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Sirolimus for Primary Immunosuppression in Heart Transplant Recipients.
    Asleh R; Briasoulis A; Kremers WK; Adigun R; Boilson BA; Pereira NL; Edwards BS; Clavell AL; Schirger JA; Rodeheffer RJ; Frantz RP; Joyce LD; Maltais S; Stulak JM; Daly RC; Tilford J; Choi WG; Lerman A; Kushwaha SS
    J Am Coll Cardiol; 2018 Feb; 71(6):636-650. PubMed ID: 29420960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Timing of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor initiation and allograft vasculopathy progression and outcomes in heart transplant recipients.
    Asleh R; Briasoulis A; Pereira NL; Boilson BA; Edwards BS; Adigun R; Maltais S; Daly RC; Lerman A; Kushwaha SS
    ESC Heart Fail; 2018 Dec; 5(6):1118-1129. PubMed ID: 30019530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation.
    Raichlin E; Bae JH; Khalpey Z; Edwards BS; Kremers WK; Clavell AL; Rodeheffer RJ; Frantz RP; Rihal C; Lerman A; Kushwaha SS
    Circulation; 2007 Dec; 116(23):2726-33. PubMed ID: 18025531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
    Raichlin E; Khalpey Z; Kremers W; Frantz RP; Rodeheffer RJ; Clavell AL; Edwards BS; Kushwaha SS
    Transplantation; 2007 Aug; 84(4):467-74. PubMed ID: 17713429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uric acid is an independent predictor of cardiac allograft vasculopathy after heart transplantation.
    Asleh R; Prasad M; Briasoulis A; Nardi V; Adigun R; Edwards BS; Pereira NL; Daly RC; Lerman A; Kushwaha SS
    J Heart Lung Transplant; 2018 Sep; 37(9):1083-1092. PubMed ID: 29802086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy of everolimus as de novo immunosuppressant on the cardiac allograft vasculopathy in heart transplant recipients.
    Choi HI; Kang DY; Kim MS; Lee SE; Ahn JM; Lee JY; Kim YH; Park DW; Jung SH; Kim JJ
    Atherosclerosis; 2022 Sep; 357():1-8. PubMed ID: 35981436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Aspirin Treatment With Cardiac Allograft Vasculopathy Progression and Adverse Outcomes After Heart Transplantation.
    Asleh R; Briasoulis A; Smith B; Lopez C; Alnsasra H; Pereira NL; Edwards BS; Clavell AL; Stulak JM; Locker C; Kremers WK; Daly RC; Lerman A; Kushwaha SS
    J Card Fail; 2021 May; 27(5):542-551. PubMed ID: 33962742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients.
    Arora S; Andreassen AK; Karason K; Gustafsson F; Eiskjær H; Bøtker HE; Rådegran G; Gude E; Ioanes D; Solbu D; Dellgren G; Ueland T; Aukrust P; Gullestad L;
    Circ Heart Fail; 2018 Sep; 11(9):e004050. PubMed ID: 30354362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stabilization of Rapidly Progressive Cardiac Allograft Vasculopathy Using mTOR Inhibition After Heart Transplantation.
    Sperry BW; Zein RE; Fendler TJ; Sauer AJ; Khumri TM; Magalski A; Austin BA; Safley D; Kao AC
    J Card Fail; 2024 Apr; 30(4):613-617. PubMed ID: 37992800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of glomerular filtration rate, renal injury markers, anemia, and angiotensin blockers use after change from calcineurin inhibitors to sirolimus in transplant patients with neoplasia versus chronic allograft nephropathy.
    Luna E; Cerezo I; Macias R; Villa J; Martinez C; Cubero J; Martinez R; Ferreira F; García C
    Transplant Proc; 2011; 43(6):2187-90. PubMed ID: 21839229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in the role of mammalian target of rapamycin inhibitors on cardiac allograft vasculopathy.
    Bellumkonda L; Patel J
    Clin Transplant; 2020 Jan; 34(1):e13769. PubMed ID: 31829455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of Malignancies in Patients Treated With Sirolimus Following Heart Transplantation.
    Asleh R; Clavell AL; Pereira NL; Smith B; Briasoulis A; Alnsasra H; Kremers WK; Habermann TM; Otley CC; Li X; Edwards BS; Stulak JM; Daly RC; Kushwaha SS
    J Am Coll Cardiol; 2019 Jun; 73(21):2676-2688. PubMed ID: 31146812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral microvascular dysfunction is associated with plaque progression and adverse long-term outcomes in heart transplant patients.
    Ozcan I; Toya T; Corban MT; Ahmad A; Lerman LO; Kushwaha SS; Lerman A
    ESC Heart Fail; 2021 Dec; 8(6):5266-5274. PubMed ID: 34510802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Layered Fibrotic Plaques Are the Predominant Component in Cardiac Allograft Vasculopathy: Systematic Findings and Risk Stratification by OCT.
    Clemmensen TS; Holm NR; Eiskjær H; Løgstrup BB; Christiansen EH; Dijkstra J; Barkholt TØ; Terkelsen CJ; Maeng M; Poulsen SH
    JACC Cardiovasc Imaging; 2017 Jul; 10(7):773-784. PubMed ID: 28330670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation.
    Stephany BR; Augustine JJ; Krishnamurthi V; Goldfarb DA; Flechner SM; Braun WE; Hricik DE; Dennis VW; Poggio ED
    Transplantation; 2006 Aug; 82(3):368-74. PubMed ID: 16906035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteinuria and baseline renal function predict mortality and renal outcomes after sirolimus therapy in liver transplantation recipients.
    Li LC; Hsu CN; Lin CC; Cheng YF; Hu TH; Chen DW; Lee CH; Nakano T; Chen CL
    BMC Gastroenterol; 2017 Apr; 17(1):58. PubMed ID: 28427351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
    Stephany BR; Boumitri M; Budev M; Alao B; Poggio ED
    J Heart Lung Transplant; 2009 Jun; 28(6):564-71. PubMed ID: 19481016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic importance of renal function 1 year after heart transplantation for all-cause and cardiac mortality and development of allograft vasculopathy.
    Arora S; Andreassen A; Simonsen S; Gude E; Dahl C; Skaardal R; Hoel I; Geiran O; Gullestad L
    Transplantation; 2007 Jul; 84(2):149-54. PubMed ID: 17667805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.